Flex Pharma (FLKS) Competitors

Flex Pharma (NASDAQ:FLKS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Is FLKS or FBIO more profitable?

Fortress Biotech has a net margin of -84.53% compared to Flex Pharma's net margin of -1,208.42%. Fortress Biotech's return on equity of 0.00% beat Flex Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flex Pharma	-1,208.42%	-98.04%	-83.37%
Fortress Biotech	-84.53%	N/A	-34.93%

Does the media prefer FLKS or FBIO?

In the previous week, Fortress Biotech had 1 more articles in the media than Flex Pharma. MarketBeat recorded 1 mentions for Fortress Biotech and 0 mentions for Flex Pharma. Fortress Biotech's average media sentiment score of 1.87 beat Flex Pharma's score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Flex Pharma	Neutral
Fortress Biotech	Very Positive

Which has higher valuation and earnings, FLKS or FBIO?

Flex Pharma has higher earnings, but lower revenue than Fortress Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flex Pharma	$840K	14.84	-$21.92M	N/A	N/A
Fortress Biotech	$57.68M	0.90	-$60.64M	-$2.78	-0.63

Do insiders & institutionals believe in FLKS or FBIO?

14.4% of Flex Pharma shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 7.6% of Flex Pharma shares are owned by company insiders. Comparatively, 33.4% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts recommend FLKS or FBIO?

Fortress Biotech has a consensus target price of $21.00, suggesting a potential upside of 1,100.00%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Flex Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flex Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, FLKS or FBIO?

Flex Pharma has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500.

Does the MarketBeat Community prefer FLKS or FBIO?

Flex Pharma received 33 more outperform votes than Fortress Biotech when rated by MarketBeat users. Likewise, 73.23% of users gave Flex Pharma an outperform vote while only 63.69% of users gave Fortress Biotech an outperform vote.

Company	Underperform	Outperform
Flex Pharma	Outperform Votes 361 73.23%	Underperform Votes 132 26.77%
Fortress Biotech	Outperform Votes 328 63.69%	Underperform Votes 187 36.31%

Summary

Fortress Biotech beats Flex Pharma on 12 of the 16 factors compared between the two stocks.